Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site.

Zhou Q, Johnson BD, Orentas RJ.

Cell Immunol. 2007 Feb;245(2):91-102. Epub 2007 Jun 1.

2.
4.

Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.

Powell KL, Stephens AS, Ralph SJ.

Cancer Immunol Immunother. 2015 Jul;64(7):861-72. doi: 10.1007/s00262-015-1695-3. Epub 2015 Apr 19.

PMID:
25893808
5.

Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.

Kobori H, Hashiguchi M, Piao J, Kato M, Ritprajak P, Azuma M.

Immunology. 2010 Jul;130(3):363-73. doi: 10.1111/j.1365-2567.2009.03236.x. Epub 2010 Feb 5.

7.

Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.

Lee H, Park HJ, Sohn HJ, Kim JM, Kim SJ.

J Surg Res. 2011 Jul;169(1):e43-50. doi: 10.1016/j.jss.2011.03.067. Epub 2011 Apr 21.

PMID:
21571303
8.

Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.

Hennies CM, Reboulet RA, Garcia Z, Nierkens S, Wolkers MC, Janssen EM.

Clin Exp Immunol. 2011 Mar;163(3):381-91. doi: 10.1111/j.1365-2249.2010.04305.x. Epub 2011 Jan 14.

9.
10.

Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.

Habib-Agahi M, Phan TT, Searle PF.

Int Immunol. 2007 Dec;19(12):1383-94. Epub 2007 Oct 31.

PMID:
17977894
12.

Dendritic cells incubated with irradiated tumor cells effectively stimulate T lymphocyte activation and induce enhanced expression of CD69, CD25 as well as production of IFNgamma and IL4.

Stegel V, Kopitar A, Jezersek Novaković B, Ihan A, Novaković S.

Int Immunopharmacol. 2006 Jan;6(1):79-89. Epub 2005 Aug 25.

PMID:
16332516
13.

Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.

Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE.

Cancer Immunol Immunother. 2007 Feb;56(2):135-46. Epub 2006 Jun 17.

PMID:
16783576
14.

Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice.

Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ.

J Immunother. 2005 Sep-Oct;28(5):449-60.

PMID:
16113601
15.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
16.

Fluorescent target array T helper assay: a multiplex flow cytometry assay to measure antigen-specific CD4+ T cell-mediated B cell help in vivo.

Quah BJ, Wijesundara DK, Ranasinghe C, Parish CR.

J Immunol Methods. 2013 Jan 31;387(1-2):181-90. doi: 10.1016/j.jim.2012.10.013. Epub 2012 Oct 30.

PMID:
23123200
17.
19.

In-vitro generation and characterisation of murine CD4+CD25+ regulatory T cells with indirect allospecificity.

Tsang J, Jiang S, Tanriver Y, Leung E, Lombardi G, Lechler RI.

Int Immunopharmacol. 2006 Dec 20;6(13-14):1883-8. Epub 2006 Sep 1.

PMID:
17161341
20.

Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.

Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN, Garçon N, Van Mechelen M, Morel S.

J Immunol. 2014 Aug 15;193(4):1920-30. doi: 10.4049/jimmunol.1400948. Epub 2014 Jul 14.

Supplemental Content

Support Center